SamChunDang, Whose Stock Soared on "Oral Obesity Drug," to Reveal Key Data for the First Time on the 21st
by Park Jeongyeon
Published 16 Apr.2026 17:28(KST)
Updated 16 Apr.2026 17:34(KST)
First Release of Pharmacokinetic (PK) Data for Oral Insulin
Bioequivalence (BE) Results for Oral Semaglutide Also Presented
Oral Delivery Data for Antibody Drugs Disclosed as Well
SamChunDang Pharmaceutical will unveil key pipeline-related data for the first time.
On April 16, SamChunDang Pharmaceutical announced that it will hold a meeting for domestic analysts on April 21. The overseas non-deal roadshow (NDR), originally scheduled for April, has been postponed to June 8-9.
The upcoming meeting will feature the release of data on oral insulin, oral semaglutide, and oral formulations of antibody drugs. This marks the company's first public disclosure of critical research data to external parties.
The pharmacokinetic (PK) data for the oral insulin candidate 'SCD0503' will be presented based on materials submitted for the European clinical trial application (IND). According to the company, they observed changes in blood concentration and onset of efficacy after oral administration that are similar to those seen with injectable formulations.
Results from the bioequivalence (BE) study of the oral semaglutide generic will also be released. Based on pre-ANDA (pre-generic approval) materials submitted to the U.S. Food and Drug Administration (FDA), the company confirmed that the generic demonstrated equivalent absorption in the body compared to the original drug, Rybelsus.
Data related to the oral formulation of antibody drugs will also be included. The company stated that it has confirmed the potential for oral delivery of recombinant fusion proteins such as etanercept and aflibercept. Generally, these drugs have high molecular weights and are easily degraded in the gastrointestinal tract, which is why they are usually administered only by injection.
SamChunDang Pharmaceutical plans to continue with presentations for overseas investors based on the data unveiled at this meeting.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.